Teva's asthma therapy chases GSK biologic with Phase III success
This article was originally published in Scrip
Executive Summary
Teva Pharmaceutical Industries will seek approval for its asthma biologic Cinquil (reslizumab) in the US, EU and other markets in the first half of 2015 based on positive results from two Phase III clinical trials, putting the therapy about six months behind GlaxoSmithKline's competing monoclonal antibody Bosatria (mepolizumab).